Psychiatry Research: Neuroimaging
Volume 146, Issue 2 , Pages 149-155 , 31 March 2006

Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study

  • Jose Mathews

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid, St. Louis, MO 63110, USA
    • ,
  • Keith S. Garcia

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid, St. Louis, MO 63110, USA
    • ,
  • Mark A. Mintun

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid, St. Louis, MO 63110, USA
    • Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
    • ,
  • Yvette I. Sheline

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid, St. Louis, MO 63110, USA
    • Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 S. Euclid, St. Louis, MO 63110, USA. Tel.: +1 314 362 8422; fax: +1 314 362 7599.

Received 12 January 2005 ,Revised 19 July 2005 ,Accepted 7 August 2005.

References 

  1. Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. Journal of Clinical Psychopharmacology. 1992;12(Supplement 2):8S–12S
  2. Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry. 2004;65:104–109
  3. Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. Journal of Psychiatric Research. 2005;39(2):161–172(Mar)
  4. De Boer T, Ruigt GSF, Berendsen HHG. The α2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology. 1995;10:S107–S118
  5. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology. 2004;14(6):457–470(Dec)
  6. Fiorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology. 1995;119(2):222–230
  7. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disorder. 2000;2:196–199
  8. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. Revised, Publication ADM 76-338. US Department of Health Education and Welfare, Bethesda MD.
  9. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  10. Keck PE, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry. 2000;61:4–9
  11. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. Journal of Nuclear Medicine. 1991;32(12):2266–2272
  12. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry. 1985;18:114–115
  13. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Archives of General Psychiatry. 1986;43:954–959
  14. Meyer JH, Cho R, Kennedy S, Kapur S. The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology. 1999;144(3):279–281
  15. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biological Psychiatry. 2004;55:217–224
  16. Nelson EB, Rielage E, Welge JA, Keck PE. An open trial of olanzapine in the treatment of patients with psychotic depression. Annals of Clinical Psychiatry. 2001;13:147–151
  17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  18. Parker G. Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. International Clinical Psychopharmacology. 2002;17:87–89
  19. Patel JG, Bartoszyk GD, Edwards E, Ashby CR. The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. Synapse. 2004;52:73–75
  20. Schatzberg AF. New approaches to managing psychotic depression. Journal of Clinical Psychiatry. 2003;64:19–23
  21. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry. 1982;39:486–487
  22. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry. 1999;46:1429–1435
  23. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT2A receptors in midlife than in late life. American Journal of Psychiatry. 2002;159:430–435
  24. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry. 2001;158:155–156
  25. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum. 1970;212:S11–S19
  26. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry. 2003;60:1079–1088
  27. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141(3):267–278

☆ Disclosure: Dr. Mathews is on the speaker's bureau of Janssen and Bristol-Myers Squibb. Dr. Garcia is on the speaker's bureau of Pfizer and GlaxoSmithKline. Dr. Sheline is on the scientific advisory board of Bristol-Myers Squibb. Dr. Mintun has no conflict of interest disclosure.

PII: S0925-4927(05)00198-8

doi: 10.1016/j.pscychresns.2005.08.003

Psychiatry Research: Neuroimaging
Volume 146, Issue 2 , Pages 149-155 , 31 March 2006

Article Tools

* Image Usage & Resolution